Q-omics provides the consensus-scored GGTA1 profile across patient tissues and cancer cell-line models. GGTA1 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, GGTA1 is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, GGTA1 RNA expression shows 23,955 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight SKCM, KIRC, and LSCC as cancer lineages where GGTA1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GGTA1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GGTA1 survival associations across molecular data types. GGTA1 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GGTA1 RNA expression–survival associations across cancer types. High GGTA1 expression shows favorable associations in SKCM, HNSC, LGG, UCEC, LUAD and CHOL. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for GGTA1 RNA expression.
This table summarizes GGTA1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for GGTA1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GGTA1 shows lower tumor expression in HNSC, COAD, BLCA, THCA and LUAD and higher tumor expression in KIRC. The KIRC box plot shows higher GGTA1 RNA expression in tumor versus normal tissue (log2 FC = +2.025, t-test p < 0.001).
This table shows molecular features associated with GGTA1 in patient tissues and cancer cell lines. In patient samples, GGTA1 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
